The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Photo of Patrik Edén

Patrik Edén

Senior lecturer

Photo of Patrik Edén

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.

Author

  • Lena Nordström
  • Sandra Sernbo
  • Patrik Eden
  • Kirsten Grønbaek
  • Arne Kolstad
  • Riikka Räty
  • Marja-Liisa Karjalainen
  • Christian Geisler
  • Elisabeth Ralfkiaer
  • Christer Sundström
  • Anna Laurell
  • Jan Delabie
  • Mats Ehinger
  • Mats Jerkeman
  • Sara Ek
Show all

Summary, in English

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.

Department/s

  • Department of Immunotechnology
  • Department of Astronomy and Theoretical Physics - Has been reorganised
  • Tumor microenvironment
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Breastcancer-genetics

Publishing year

2014

Language

English

Pages

98-108

Publication/Series

British Journal of Haematology

Volume

166

Issue

1

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Hematology

Status

Published

ISBN/ISSN/Other

  • ISSN: 0007-1048